Results 201 to 210 of about 65,698,273 (265)

Centanafadine (Simtriyo®): a first-in-class triple reuptake inhibitor approved for attention-deficit/hyperactivity disorder (ADHD). [PDF]

Med Chem Res
Hu L.
europepmc   +1 more source

Symptom epidemiology, demographic correlates, and differentiation between cognitive disengagement syndrome symptoms and ADHD symptoms in a large nonprobability sample of Iranian adolescents and adults. [PDF]

BMC Psychiatry
Abdolmohamadi K, Brand S, Alimohamadi A, Sadeghi-Bahmani D.   +3 more
europepmc   +1 more source

Pattern of sensory processing disorder in school-aged preterm children with attention-deficit hyperactivity disorder. [PDF]

PCN Rep
Nunes MEN, Caldas CATC, Liporaci NM, Zuanetti PA, Fernandes ACP, Portugal CA, Hamad APA.   +6 more
europepmc   +1 more source